Codexis to Report Third Quarter 2022 Financial Results on November 3
October 20, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 20, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (Nasdaq: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that it will...
Codexis Announces Appointment of Rahul Singhvi, Sc.D., to Board of Directors
October 03, 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
Codexis Announces Appointment of Kevin Norrett as Chief Operating Officer
October 03, 2022 08:00 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Oct. 03, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the appointment...
Codexis’ 2022 Protein Engineering Forum Showcases Recent Industry Success and Emerging Innovations in the Field
September 14, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., Sept. 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced the recent...
Codexis Reports Second Quarter 2022 Financial Results
August 04, 2022 16:05 ET
|
Codexis, Inc.
Total Revenue up 51% and Product Revenue up 135% YOY 2022 Total Revenue Guidance of $135M-$141M, Including Product Revenues of $112M-$118M REDWOOD CITY, Calif., Aug. 04, 2022 (GLOBE NEWSWIRE) --...
Codexis and Molecular Assemblies Announce Execution of Commercial License and Enzyme Supply Agreement for Optimized TdT Enzyme for Enzymatic DNA Synthesis
August 02, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif. and SAN DIEGO, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, and Molecular...
Codexis Announces CEO Transition Effective August 9, 2022
July 18, 2022 16:05 ET
|
Codexis, Inc.
Dr. Stephen Dilly, Board member and biotechnology veteran, named the next President and CEOJohn Nicols to retire after ten years leading the transformation and growth of Codexis REDWOOD CITY,...
Codexis Announces Agreement with Pfizer to Supply Enzyme for the Manufacture of PAXLOVID™ (nirmatrelvir tablets; ritonavir tablets)
July 14, 2022 16:06 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced that the Company...
Codexis Announces Preliminary Second Quarter 2022 Results and Updates Guidance
July 14, 2022 16:05 ET
|
Codexis, Inc.
REDWOOD CITY, Calif., July 14, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the promise of synthetic biology, today announced preliminary...
Codexis Announces the Publication of Research Demonstrating Proof of Concept for Chemoenzymatic Site-Selective Bioconjugation of Native Peptides
June 17, 2022 08:00 ET
|
Codexis, Inc.
Collaboration with Merck published in Science magazine REDWOOD CITY, Calif., June 17, 2022 (GLOBE NEWSWIRE) -- Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company enabling the...